Cancer Immunotherapy: CAR-T, Checkpoint Inhibitors, and Vaccines

Core Idea

Cancer immunotherapy leverages the immune system to attack tumors via multiple mechanisms: CAR-T cells (engineered T cells expressing synthetic tumor-specific receptors), checkpoint inhibitors (blocking PD-1/PD-L1 or CTLA-4), therapeutic cancer vaccines (inducing/enhancing anti-tumor T cells), and monoclonal antibodies (ADCC and CDC). Combination therapies are often superior to single modalities.

How It's Best Learned

Compare mechanism and efficacy of CAR-T, checkpoint blockade, and vaccine approaches across cancer types. Study how tumors develop resistance (e.g., loss of antigen, PD-L1 upregulation).

Common Misconceptions

CAR-T cells are not TCRs; they are synthetic receptors that do not require MHC presentation. Checkpoint blockade has clinical benefit in only ~30-40% of patients; predictive biomarkers remain imperfect.

Explainer

From your study of immune checkpoints and cytotoxic T cells, you know that the immune system has powerful mechanisms to kill abnormal cells — but also built-in brakes that prevent overactivation. Cancer immunotherapy is fundamentally about tipping this balance: releasing the brakes, upgrading the weapons, or teaching the immune system to recognize tumors it has been ignoring. The three major therapeutic strategies — checkpoint inhibitors, CAR-T cells, and cancer vaccines — each attack this problem from a different angle.

Checkpoint inhibitors work by blocking the "off switches" that tumors exploit to evade immune destruction. You learned that molecules like PD-1 on T cells and CTLA-4 are negative regulators that dampen T cell activation — a necessary safeguard against autoimmunity. Many tumors upregulate the ligand PD-L1 on their surface, effectively pressing the PD-1 brake on any T cell that recognizes them. Drugs like pembrolizumab and nivolumab are monoclonal antibodies that bind PD-1 or PD-L1 and block this interaction, releasing the brake and allowing tumor-specific T cells to attack. Ipilimumab blocks CTLA-4, which operates earlier in T cell activation (primarily in lymph nodes during priming). The clinical reality is that checkpoint blockade works spectacularly in some cancers (melanoma, lung cancer, renal cell carcinoma) but benefits only about 30–40% of patients — effectiveness depends on factors like tumor mutational burden, pre-existing T cell infiltration, and the tumor's antigen landscape.

CAR-T cell therapy takes a more engineered approach. Rather than relying on the patient's existing T cells to find the tumor, clinicians extract the patient's T cells, genetically modify them to express a chimeric antigen receptor (CAR) — a synthetic receptor that combines an extracellular antibody fragment targeting a specific tumor surface protein with intracellular T cell signaling domains — and then infuse these engineered cells back into the patient. The critical difference from natural T cell recognition is that CARs do not require MHC presentation: they bind directly to surface proteins on tumor cells, bypassing one of the major ways tumors escape detection (by downregulating MHC). CAR-T therapy has achieved remarkable remission rates in certain blood cancers (B-cell lymphomas and leukemias targeting CD19), but solid tumors remain challenging due to the immunosuppressive tumor microenvironment, poor T cell infiltration, and the difficulty of finding surface antigens unique to the tumor.

Cancer vaccines aim to prime or boost the patient's own immune response against tumor-specific antigens — neoantigens generated by tumor mutations, or overexpressed normal proteins. Unlike preventive vaccines (which block infection), therapeutic cancer vaccines are given after cancer has developed, and they must overcome the tumor's existing immune evasion. Approaches include dendritic cell vaccines (loading the patient's dendritic cells with tumor antigens ex vivo), peptide or mRNA vaccines targeting predicted neoantigens, and oncolytic viruses that infect and lyse tumor cells while stimulating immune responses. Increasingly, the field recognizes that combination therapies — such as checkpoint inhibitors paired with vaccines or CAR-T cells followed by checkpoint blockade — outperform single approaches, because each modality addresses a different bottleneck in the anti-tumor immune response.